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A Cell Surface Amine Oxidase
Directly Controls Lymphocyte Migration
to the semicarbazide-sensitive monoamine oxidases
([SSAO], EC 1.4.3.6) (Smith et al., 1998). VAP-1 is a type
2 integral membrane protein with a large catalytically
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active extracellular domain. The role of SSAO activity*MediCity Research Laboratory
and its physiological substrates, if any, in leukocyte-Turku University and National Public Health Institute
endothelial interaction are completely unknown. TheDepartment in Turku
SSAO enzymes catalyze the general reaction R-CH2-†Department of Biochemistry and Pharmacy
NH21O21H20!R-CHO1H2O21NH3, in which a primaryA˚bo Akademi University
amine is oxidatively deaminated to the correspondingTurku FIN-20520
aldehyde with a simultaneous release of hydrogen per-Finland
oxide and ammonium (McIntire and Hartmann, 1993;
Klinman and Mu, 1994; Lyles, 1996). VAP-1 was the
first molecularly defined transmembrane member of thisSummary
enzyme group in mammals, and it accounts for z90%
of cellular SSAO activity (Jaakkola et al., 1999). Notably,Lymphocytes leave the blood using a sequential adhe-
SSAO are very different from the well-characterizedsion cascade. Vascular adhesion molecule-1 (VAP-1)
monoamine oxidases A and B in respect to subcellularis a surface-expressed endothelial glycoprotein, which
localization, substrates, cofactors, inhibitors, and nucle-belongs to a distinct subgroup of monoamine oxi-
otide sequence (Klinman and Mu, 1994; Lyles, 1996).dases. We show here that catalytic activity of VAP-1
Although the SSAO reaction has been known sinceon primary endothelial cells directly regulates lympho-
the 50’s in biochemical terms (Bergeret et al., 1957), thecyte rolling under defined laminar shear. VAP-1 seems
physiological function(s) of these enzymes has remainedto bind to a primary amino group presented on the
enigmatic. Even the physiological substrates of SSAOlymphocyte surface and oxidatively deaminate it in a
are not known, even though two soluble amines, methyl-reaction, which results in the formation of a transient
amine and aminoacetone, formed at low concentrationscovalent bond between the two cell types. Instead,
during intermediary metabolism in humans, can be de-soluble reaction products (aldehydes and hydrogen
aminated by SSAO in vitro (Klinman and Mu, 1994; Lyles,peroxide) are not needed for the VAP-1-dependent
1996). Most functional studies have recently focused onrolling. Enzymatic regulation of lymphocyte adhesion
the possible role of SSAO in vasculopathies, since SSAOto endothelium provides a previously unrecognized
inhibitors seem to prevent atherosclerosis-related pro-rapid way of controlling the extravasation process.
cesses in diabetic animals (Yu and Deng, 1998).
We hypothesized that the enzymatic activity mightIntroduction
contribute to the adhesive function of VAP-1. This could
involve locally released soluble reaction products, sincePhysiological immune surveillance is dependent on the
aldehydes could function as direct cross-linkers be-continuous patrolling of lymphocytes between the blood
tween the lymphocyte and endothelial cell, and hydro-and different lymphoid organs. Although absent or only
gen peroxide is known to be a signaling molecule (Finkel,present at very low levels in normal non-lymphoid tis-
1998; Kunsch and Medford, 1999; Bogdan et al., 2000).sues, vast numbers of lymphocytes can accumulate in
In fact, exogenously added hydrogen peroxide upregu-various affected tissues and organs in many inflamma-
lates the expression of other endothelial molecules (e.g.,
tory diseases (Springer, 1994; Butcher and Picker, 1996;
P-selectin and ICAM-1) needed for efficient leukocyte
Salmi and Jalkanen, 1997). One of the important mole-
emigration (Patel et al., 1991; Bradley et al., 1993; John-
cules in controlling lymphocyte exit from the blood is ston et al., 1996). In addition, if the VAP-1 substrates
vascular adhesion protein-1 (VAP-1). It is a homodimeric were cell-surface bound amines (e.g., aminosugars or
170–180 kDa endothelial glycoprotein (Salmi and Jalka- free NH2 groups in amino acids), formation of a transientnen, 1992, 1996). VAP-1 mediates lymphocyte binding covalent bond (Schiff base) between the SSAO enzyme
to venules in human tissue sections, and a VAP-1-trans- and its substrate (Klinman and Mu, 1994; Wilmot et al.,
fected endothelial cell line supports lymphocyte adher- 1999) would directly hold the two cell types together.
ence in vitro (Salmi and Jalkanen, 1992; Smith et al., Here, we were able to isolate primary, enzymatically
1998). In vivo experiments with antibodies suggest that active VAP-1 positive endothelial cells and use them to
VAP-1 functions already relatively early in the process dissect the adhesive function of VAP-1 in lymphocyte
of lymphocyte extravasation (Salmi et al., 1997), which extravasation under physiologically relevant conditions.
encompasses successive tethering, rolling, activation, Using an in vitro flow chamber assay, we show that
firm adhesion, and transmigration steps (Springer, 1994; VAP-1 first comes into play at the rolling step. Most
Butcher and Picker, 1996; Premack and Schall, 1996; importantly, we demonstrate how a VAP-1-mediated
Cyster, 1999; Melchers et al., 1999; Shimizu et al., 1999) SSAO activity indeed critically mediates lymphocyte
Cloning of VAP-1 surprisingly revealed that it belongs binding to vascular endothelium. Ecto-enzymatic regu-
lation of lymphocyte migration provides an alternative
way of controlling leukocyte extravasation and hence‡ To whom correspondence should be addressed (e-mail: marko.
salmi@utu.fi). our immune defense.
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Figure 1. Characterization of VAP-1 in Rabbit Heart
(A–C) Cardiac vessels react with anti-VAP-1 mAbs TK8-14 (strongly) and 2D10 (faintly). Brown precipitate indicates the positive reactivity in
the immunoperoxidase staining of frozen sections. Bar, 100 mm.
(D–E) Isolated endothelial cells but not control VAP-1 CHO transfectants take up acetylated LDL (red granular fluorescence). Bar, 20 mm.
(F) Isolated heart endothelial cells are surface positive for VAP-1. Cells were stained for VAP-1 and control antigens with the indicated mAbs
and analyzed by flow cytometry.
(G) Rabbit endothelial VAP-1 displays a similar molecular mass to human VAP-1 originating from tonsil or from Ax and CHO cells transfected
with VAP-1 (but not from mock transfectants). The sizes of molecular mass standards (in kDa) are indicated at left, and the black arrow points
to the z180 kDa dimeric and the white arrow to the z90 kDa monomeric form of VAP-1.
All experiments were repeated at least three times with similar results.
Results collagenase digestion and immunomagnetic selection.
The isolated cells maintained their endothelial proper-
ties in culture given that they continued to take up ace-VAP-1 Is Expressed on the Surface of Cultured
Endothelial Cells tylated LDL (Figures 1D–1E). This compound is a com-
monly used endothelial marker, since only endothelialVessels in rabbit heart contain VAP-1 positive endothe-
lial cells (Figures 1A–1C), as shown by their reactivity cells and macrophages, but not fibroblasts or smooth
muscle cells, contain a receptor for its endocytosiswith two different monoclonal antibodies (mAbs) initially
raised against human VAP-1 (Kurkija¨rvi et al., 1998). The (Voyta et al., 1984). In six independent cultures from
different rabbits, 50%–70% of cells displayed the char-endothelial cells from the hearts were isolated using a
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Figure 2. Endothelial VAP-1 Is an SSAO
(A) Substrate specificity of VAP-1/SSAO was
determined in competition assays using [14C]-
benzylamine (6 mM) and 500 mM of unlabeled
amines: Bz, benzylamine; PEA, b-phenyleth-
ylamine; MA, methylamine; Tyr, tyramine;
Tryp, tryptamine; and Hist, histamine. The
cells were also incubated with 100 mM semi-
carbazide (Sc), 5 mM hydroxylamine (HA), or 1
mM clorgyline (Clorg) before addition of [14C]-
benzylamine.
(B) Effect of anti-VAP-1 mAbs and PBL on
the SSAO activity. Endothelial monolayer was
preincubated with the indicated anti-VAP-1
and control mAbs (200 mg/ml) or with PBL
suspension (2 3 106 cells/well) 30 min before
addition of [14C]-benzylamine. Data represent
mean 6 SEM of indicated number of experi-
ments performed in duplicate. *P , 0.05 as
compared to control samples.
(C) Substrate specificity of VAP-1/SSAO was
determined in fluorometric assay using 1 mM
of the indicated amines as substrates. Data
represent mean 6 SEM of four to six experi-
ments performed in duplicates.
(D) SSAO-mediated formation of hydrogen
peroxide during incubation of endothelial
cells with PBL. Endothelial monolayer was
preincubated with the indicated mAbs (100
mg/ml) 30 min prior to addition of PBL suspen-
sion (or their lysate) and Amplex Red reagent
as described in Experimental Procedures.
The plates were incubated for 2 hr in dark,
and the amount of the H2O2 formed was de-
tected (mean 6 SEM; n 5 6).
(E) Rate of benzylamine oxidation by endo-
thelial SSAO versus substrate concentration
plot. Cultured endothelial cells were preincu-
bated with various mAbs (100 mg/ml) 30 min
prior to addition of the increasing concentra-
tions of benzylamine (5–500 mM). Data repre-
sent mean 6 SEM of three experiments per-
formed in duplicates.
(F) Kinetic parameters of endothelial SSAO. Endothelial cells were incubated with various benzylamine concentrations in the absence (control)
and presence of certain mAbs (as shown in [E]) and Vmax and Km values were calculated using a nonlinear curve fitting program based on the
Michaelis-Menten equation.
(G) The number of VAP-1 molecules in the cultured cells were analyzed by displacement binding studies using FITC-labeled and nonlabeled
mAb TK8-14 as detailed in the Experimental Procedures. A representative experiment from three is shown.
acteristic granular positivity. The rest are probably the reaction product H2O2 was quantified directly after
incubation of the cells with various potential substratessmooth muscle cells, which are also VAP-1 positive
(Jaakkola et al., 1999). Flow cytometric analyses re- using Amplex Red-labeled phenoxazine reagent and flu-
oropolarometer.vealed that the cultures yielded an essentially pure pop-
ulation of VAP-1 surface positive cells (Figure 1F). In Addition of [14C]-benzylamine to the lysates of cultured
endothelial cells was accompanied by formation of [14C]-immunoblotting, rabbit VAP-1 from the cultured cells
showed similar molecular mass (180 kDa dimer and 90 benzaldehyde in the bathing medium (control). This re-
action was completely inhibited by carbonyl reactivekDa monomer) to that of human VAP-1 obtained from
tissues or from transfectants (Figure 1G). Thus, these inhibitors of SSAO, semicarbazide and hydroxylamine,
but not with clorgyline (Figure 2A), which inhibits thecultured cells are mostly endothelial cells displaying
VAP-1 on their surface. unrelated monoamine oxidases A and B (Lyles, 1996).
In competition assays, several unlabeled monoamines
were tested for their ability to prevent catalytic oxidationVAP-1 Is Enzymatically Active in Cultured Cells
Monoamine oxidase activity of the cultured endothelial of [14C]-benzylamine, and the following rank order was
established: benzylamine . b-phenylethylamine . meth-cells was assayed using two independent approaches.
In the radiochemical method [14C]-labeled benzylamine, ylamine . tryptamine $ tyramine . histamine (Figure
2A). Pretreatment of intact monolayers of endotheliala prototypic (but artificial) substrate for SSAO (Klinman
and Mu, 1994) was used with or without competing cold cells with the SSAO inhibitors also completely abrogated
amine oxidase activity. Taken together, these data indi-substrates, and the formation of radiolabeled benzalde-
hyde was measured. In the other assay, formation of cate that rabbit heart endothelial cells possess high
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oxidative activity toward benzylamine and other mono-
amines, with hallmark characteristics of SSAO.
Function blocking anti-VAP-1 mAbs TK8-14 and 2D10
did not have any effect on oxidation of [14C]-benzylamine
by VAP-1 (Figure 2B). Using this particular radiochemical
assay, coincubation of endothelial monolayers with lym-
phocytes only was also without significant effect. Treat-
ment of endothelial cells with mAb TK8-14 prior to their
incubation with PBL, however, caused significant de-
crease of the rate of [14C]-benzylamine oxidation (Figure
2B). Assuming that PBL contain a physiologically rele-
vant substrate for endothelial VAP-1, one possible ex-
planation of these data is that anti-VAP-1 mAb TK8-
14 induces specific conformational changes of VAP-1/
SSAO molecule, thus making the enzyme more effective
in oxidating its lymphoid substrate.
To test this possibility, we used a sensitive fluoromet-
ric assay for determination of the reaction product H2O2
in the assay medium. To discriminate the amount of
H2O2 formed via SSAO-mediated reaction, the control
wells were subjected to the identical treatments in the
presence of hydroxylamine and semicarbazide, and
these values were subtracted from the total amount of
the hydrogen peroxide formed. The results showed that
cultured endothelial cells are able to oxidize with differ-
ent efficacy various exogenous monoamines and hista-
mine (Figure 2C) and the rank order is comparable with
competitive studies using [14C]-benzylamine oxidation Figure 3. Lymphocytes Roll and Adhere on VAP-1 Positive Endothe-
lial Cells under Defined Laminar Shear(Figure 2A). Importantly, low but significant formation of
The cell pointed out by the black arrow has rolled 35 mm and theH2O2 in the assay medium (3.9 6 1.2 pmoles per hour;
one indicated by the arrowhead has rolled 52 mm during the 3 sn 5 6) was detected during lymphocyte-endothelial
interval. Another fast rolling cell (curved arrow) has entered the fieldcoincubation in the absence of any exogenous amines
at the time interval between the two video frames. All the other cells(Figure 2D). SSAO catalyzed H2O2 production was in- remain stably adherent. Noninteracting cells move too fast (from
creased (three to four times) after pretreatment of endo- right to left at a shear of 0.8 dyn/cm2) to be seen in static pictures.
thelial cells with anti-VAP-1 mAbs before PBL coincuba- Bar, 20 mm.
tion, whereas control mAbs were without effect (Figure
2D). Disruption of PBL by sonication and addition of the
obtained lysate to the endothelial cells did not cause nM) and with saturating binding capacity (Bmax 80 fmol/
further activation of H2O2 production, thus excluding the 106 cells: that is the equivalent of about 50,000 VAP-1
possibility of the leakage of intracellular amines or other molecules per cell). Since the benzylamine oxidizing ac-
potential intracellular substrates from the lymphoid tivity of VAP-1 is equal to z160,000 catalytic reactions
cells. These data support the hypothesis that lymphoid per cell per second at Vmax (950 pmol/106 cells/h), the
cells contain surface-associated substrates that can be reaction can be approximated to take about 0.3 s.
oxidized by endothelial VAP-1/SSAO molecules during
the course of leukocyte-endothelial interaction and this
Anti-VAP-1 mAbs Inhibit Lymphocyte Rollingprocess can be specifically regulated by anti-VAP-1
under Flow ConditionsmAbs.
To study the role of VAP-1/SSAO in leukocyte extravasa-To further elucidate the mechanism of anti-VAP-1
tion, flow chamber assays were used to mimic the physi-mAb action, kinetic analyses of the endothelial SSAO
ological shear conditions. In this assay, the hydrody-activity were carried out. Figure 2E shows a curvilinear
namic shear-dependent rolling of lymphocytes along theMichaelis-Menten plot describing the rate of benzyl-
endothelial cell monolayer and the final shear-resistantamine oxidation in the absence (control) and presence of
stable adhesion of lymphocytes can be dynamically ana-fixed amounts of certain mAbs. Both anti-VAP-1 mAbs,
lyzed by videomicroscopy. In all experiments, unstimu-TK8-14 and 2D10, but not irrelevant mAb HB9771, signif-
lated rabbit endothelial cells were used, since they al-icantly increased the maximal velocity (Vmax) and the
ready were VAP-1 positive and we do not know whichapparent Michaelis-Menten constant (Km), as summa-
mediators upregulate VAP-1.rized in Figure 2F. These data confirm the conforma-
Freshly isolated peripheral blood lymphocytes teth-tional changes of VAP-1/SSAO molecule after treatment
ered (i.e., lymphocyte from the free flow made a transientof the endothelial cells with anti-VAP-1 mAbs.
contact with endothelial cell), rolled (i.e., moved to theThe number of VAP-1 molecules on the endothelial
direction of flow in contact with the endothelial cell sur-surface was quantified in displacement binding studies
face), and stably bound (i.e., remained stationary for atwith FITC-labeled and unlabeled anti-VAP-1 mAb TK8-
least 30 s) to cultured endothelial cells. When perfused14 (Figure 2G). The kinetic data revealed that mAb TK8-
14 binds to the endothelial cells with high affinity (Kd 60 over the plate at a laminar shear stress of 0.8 dyn/cm2,
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Figure 4. Anti-VAP-1 mAbs Block Lympho-
cyte Rolling
The number of (A) firmly bound and (B) rolling
lymphocytes on the endothelial monolayer
was defined after pretreatment with anti-
VAP-1 and control mAbs (100 mg/ml). Number
of cells in the presence of nonbinding control
mAb defines 100% interaction. The shear
stress was 0.8 dyn/cm2. (C) The number of
firmly bound and rolling cells was determined
after pretreatment of the endothelial cells
with lower doses of anti-VAP-1 and control
mAbs (25 mg/ml) at the indicated shear
stresses (0.8 or 1.0 dyn/cm2). The number of
independent assays is shown in parentheses.
*p , 0.05 and **p , 0.01 when compared to
controls.
there were 58.0 6 8.2 rolling cells/mm2 (n 5 23) and pared to those observed at 0.8 dyn/cm2. Nevertheless,
anti-VAP-1 mAb still significantly inhibited both rolling226.5 6 30.3 stably adherent cells/mm2 (n 5 23) on the
endothelial cell monolayers (Figure 3). Strikingly, two and stable adhesion (Figure 4C). Hence, when the func-
tion of VAP-1 is ablated by mAbs almost 50% of lympho-independent anti-VAP-1 mAbs (at 100 mg/ml) signifi-
cantly diminished the number of adherent cells by 30%– cyte-endothelial interactions are abolished at the rolling
step.46% (Figure 4A). To further dissect, whether VAP-1 is
already involved at the earlier steps of the adhesion
cascade, the number of rolling cells was counted next. SSAO Activity Regulates Lymphocyte Rolling
The current approach allowed us to test the contributionLymphocyte rolling was only marginally affected by the
low-avidity anti-VAP-1 mAb 2D10. However, the number of enzymatic activity of VAP-1 to its adhesive function.
To that end, the endothelial cells were preincubated withof rolling cells decreased significantly after blocking with
anti-VAP-1 mAb TK8-14 (Figure 4B), which recognizes chemical SSAO inhibitors. These treatments resulted in
a .95% inhibition of SSAO activity (Figure 2A) withouta different epitope of VAP-1. In control experiments,
preincubation of endothelial cells with a nonbinding or any adverse effects on endothelial cell viability. Strik-
ingly, the inhibition of SSAO activity reduced the numbera binding control mAb did not alter the number of rolling
or adherent cells on VAP-1 positive monolayers (Figure of firmly adherent cells under flow conditions by more
than 40% (Figure 5A). SSAO activity was important for4). Moreover, if the concentration of the anti-VAP-1 mAb
TK8-14 was reduced to 25 mg/ml, the inhibitory effect the endothelial cells already to support lymphocyte roll-
ing (Figure 5B). The SSAO inhibitors also very effectivelyon both firm adhesion and rolling was sustained (Figure
4C). If the shear stress was increased to 1.0 dyn/cm2, reduced the number of rolling and adherent cells, when
the analyses were performed at higher shear stress (1.0the number of firmly bound (156 6 27/mm2; n 5 7) and
rolling (36 6 7/mm2; n 5 7) cells decreased when com- dyn/cm2; Figure 5C). In contrast, clorgyline, an inhibitor
Immunity
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Figure 5. SSAO Activity Is Needed for Lym-
phocyte Rolling
The number of (A) firmly bound and (B) rolling
lymphocytes on the endothelial monolayer
was analyzed with and without pretreatment
of endothelial cells with SSAO and MAO in-
hibitors and mAbs. Number of cells in the
presence of medium alone defines 100% in-
teraction. Shear stress was 0.8 dyn/cm2. (C)
The number of rolling and adherent cells de-
termined after endothelial pretreatment with
SSAO inhibitors at a higher shear stress (1.0
dyn/cm2). The number of independent assays
is shown in parentheses. *p , 0.05 and **p ,
0.01 when compared to controls. (D) Stability
of adherent cells is independent of VAP-1.
The number of firmly adherent cells was de-
fined at the 10 min time point of the standard
flow assay (5100% adherence). Thereafter,
the shear was increased at 45 s intervals by
the indicated steps up to 6.5 dyn/cm2. The
number of cells remaining adherent at the end
of each shear increment was determined. The
results are the mean of two to four experi-
ments. The standard errors (,10% in each
case) are omitted for clarity.
of MAO A and B activity, had no inhibitory effect on by anti-VAP-1 mAbs and SSAO inhibitors. It also remains
possible that an additional population would be affectedeither rolling or firm adhesion (Figure 5). Thus, inhibition
of SSAO activity reduces lymphocyte rolling even when by either treatment but that it would be too small to
reveal an additive effect in this assay. Together, theseall other adhesion molecules remain intact.
Because both anti-VAP-1 mAbs and SSAO inhibitors data show that SSAO activity can directly regulate leuko-
cyte-endothelial cell contacts under defined laminarprevented lymphocyte adhesion, we tested whether
they had an additive effect. Combined pretreatments flow.
with antibodies and SSAO inhibitors caused a compara-
ble inhibitory effect on the number of rolling and firmly Blocking of VAP-1/SSAO Does Not Affect
Tethering or Firmness of Bindingbound cells to that seen with the either treatment sepa-
rately (Figures 5A and 5B). Hence, it is possible that To see if VAP-1 is involved already in the initial capture
of freely flowing cells, we analyzed the number of lym-binding of the same lymphocyte population is targeted
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phocytes that directly tethered on endothelial cells (pri- resulted in no change in the expression of any studied
endothelial adhesion molecule (ICAM-1, ICAM-2, E-selec-mary tethers) under shear of 0.8 dyn/cm2. These analy-
ses showed that blockade of VAP-1 by mAbs or SSAO tin, VCAM-1, and CD31) in TNF-a 1 IL-1-b-induced HUVEC
(data not shown).inhibitors does not cause a detectable effect on the
tethering process. For example, there were 20.3 primary
tethers/mm2 in control-treated samples and 20.8 teth- Molecular Modeling of an Amino Acid
ers/mm2 in samples that had been preincubated with a Substrate for VAP-1
combination of mAb TK8-14, SC, and HA. Hence, lym- The possibility that an amino group on lymphocyte sur-
phocyte tethering to the endothelial cells in this assay face molecule could be accepted as a substrate for the
is VAP-1 independent. catalytic center present inside the VAP-1 molecule was
A detachment assay was then used to analyze the further evaluated by molecular modeling. The extracellu-
shear resistance of bound lymphocytes, which is indica- lar part of VAP-1 was modeled based on the known
tive of the binding strength (Lawrence et al., 1994). The crystal structures of other members of SSAO family. In
shear was increased step-wise at regular intervals, and Figure 7A, a surface view shows that a polypeptide can
the number of cells remaining adherent at each shear accommodate into a groove on the surface of VAP-1 at
stress was determined (Figure 5D). The results showed a position that overlays the catalytic center. From the
that only few adherent lymphocytes were released at side view, it is clearly evident that the free amino group
any shear rate tested and there were no significant dif- of the lysine side chain easily enters the cavity leading
ferences between control, anti-VAP-1 mAb, and SSAO to the catalytic center (Figure 7B). The lysine side chain
inhibitor treated cells. Thus, the firmness of binding of is also long enough to allow the free NH2 group to make
those lymphocytes, which still can bind via other adhe- contacts with the catalytically active TOPA-quinone
sion molecules to endothelial cells when the function of modified active tyrosine residue (Tyr 471 of VAP-1) at the
VAP-1 is blocked, is unaffected by concomitant inactiva- bottom of the cavity (Figure 7B). Hence, a lymphocyte
tion of VAP-1. surface molecule could provide a surface bound amino
group for oxidation by VAP-1, which would result in a
transient covalent binding between the lymphocyte andSSAO Reaction Products and Lymphocyte Adhesion
the endothelial cells.SSAO activity might regulate lymphocyte rolling on en-
To test this hypothesis directly, a lysine contain-dothelial cells by virtue of its biologically active end
ing peptide fitting into the groove was synthesizedproducts. Therefore, we tested the effects of exoge-
(GGGGKGGGG), and its effect on endothelial SSAO ac-nously administered substrate (benzylamine) and reac-
tivity was determined. Pretreatment of the cultured cellstion products (benzaldehyde, hydrogen peroxide) on
with this peptide (1 mM) prior to incubation with 1 mMlymphocyte rolling and adhesion under laminar shear
benzylamine decreased SSAO-mediated H2O2 produc-stress. The results clearly showed that inclusion of SSAO
tion (48.7 6 6.8% of the control activity measured in thereaction products benzaldehyde or H2O2 was ineffective
absence of peptides; n 5 5, p , 0.01). In contrast, ain modulating leukocyte-endothelial cell contacts in this
bulky control peptide (PHEPTYPDF) predicted not to fitassay (Figures 6A and 6B). In fact, when benzylamine
into the groove was without effect (90.5 6 5.5% of thewas provided as an exogenous substrate for VAP-1 the
control activity, n 5 5). Irrelevant lysine-containing pep-number of firmly adherent cells was significantly re-
tides had no effect on SSAO activity either. We wereduced, and the number of rolling cells also showed a
unable to detect H2O2 formation if only the peptide wasdeclining tendency (Figures 6A and 6B). These data ar-
incubated with the endothelial cells. This probably onlygue against a role for soluble cross-linking aldehydes
reflects the fact that our model peptide is not a perfector reactive oxygen species produced by VAP-1 as mo-
match with a natural substrate but can, nevertheless,lecular mediators of the SSAO activity on leukocyte roll-
enter the catalytic cavity and interfere with the bindinging and firm binding. The inhibition by lymphocyte-endo-
of the soluble amines. Since lymphocytes coincubatedthelial cell interactions in a presence of benzylamine is
with the endothelial cells in the absence of any exoge-compatible with the abovementioned possibility that it
nous substrate resulted in VAP-1-mediated H2O2 forma-as an exogenuos soluble amine competes with a lym-
tion (Figure 2D), a lymphocyte surface peptide can mostphocyte surface-bound molecule for binding to VAP-1/
likely present suitable polypeptide substrate(s) for endo-SSAO during the rolling.
thelial VAP-1 for the SSAO catalyzed reaction.We showed in additional control experiments that
anti-VAP-1 mAbs or SSAO inhibitors have no general
inhibitory effect on lymphocyte adhesion to endothe- Discussion
lium. For this purpose, HUVECs, which are practically
negative for VAP-1 protein and lack SSAO activity (Salmi We have demonstrated here that, during the multistep
adhesion cascade, VAP-1 first comes into play afterand Jalkanen, 1995; data not shown), were pretreated
with the same concentrations of the compounds that tethering when lymphocytes start to roll on endothelial
cells under physiological laminar shear. Inhibition of lym-had been used for the assays with cardiac endothelium.
Lymphocytes rolled (75 cells/mm2) and firmly bound (345 phocyte rolling after VAP-1 blockade by mAbs also
translates into a significant reduction in the number ofcells/mm2) well to the activated HUVEC at shear of 0.8
dyn/cm2 under control conditions. Notably, neither anti- firmly bound cells. Most importantly, the current experi-
ments show that the catalytic activity of VAP-1/SSAO isVAP-1 mAbs, SSAO inhibitors, nor benzylamine had any
significant inhibitory effect on either rolling or firm adhe- directly involved in leukocyte-endothelial cell contacts.
Inhibition of the enzymatic activity of VAP-1 also resultssion on HUVEC (Figure 6C). Moreover, these treatments
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Figure 6. SSAO Reaction Products and Lym-
phocyte Adherence
The number of (A) firmly bound and (B) rolling
lymphocytes on the cardiac endothelial mono-
layer was analyzed with and without pretreat-
ment of endothelial cells with SSAO sub-
strates and end products. Number of cells in
the presence of medium alone defines 100%
interaction. In all experiments, shear stress
was 0.8 dyn/cm2. The number of independent
assays is shown in parentheses. *p , 0.05
and **p , 0.01 when compared to controls.
(C) In control experiments, activated, practi-
cally VAP-1 negative HUVEC (from four indi-
viduals) were used in four independent flow
experiments at 0.8 dyn/cm2.
in a .40% reduction in the number of rolling and firmly with VAP-1. This binding can be inhibited with the anti-
VAP-1 mAbs. In this respect, the oligosaccharide modifi-bound lymphocytes under shear. The kinetics of an en-
zyme reaction would be compatible with the require- cations of VAP-1, which in molecular models extend
outward from the planar outer surface of the moleculements for rapid formation and dissociation of bonds
between the rolling lymphocyte and endothelial cells. (Salminen et al., 1998), are likely crucial in recognizing
an unknown counterreceptor of VAP-1 on lymphocytesHence, enzymatic regulation of lymphocyte extravasa-
tion provides a novel pathway for controlling movement (Salmi and Jalkanen, 1996). When the lymphocyte binds
to the anti-VAP-1-defined epitope of VAP-1, a conforma-of immune cells within the body.
Our findings with enzymatic and flow assays would tional change in VAP-1 molecule takes place. Thereafter,
a surface-associated amino group of the lymphocytebest fit to a following model. A freely flowing lymphocyte
first tethers to the endothelial cells in a VAP-1-indepen- can serve as a substrate for the catalytic site of endothe-
lial VAP-1 (see below). Thereby, the rolling cell woulddent manner. Tethering most likely takes place via bind-
ing of selectins to their oligosaccharide-based ligands become covalently, but transiently, linked to the endo-
thelial VAP-1 via a Schiff base. Whether the same lym-(McEver et al., 1995; Kansas, 1996). Once in contact
with the endothelial cells, the lymphocyte next interacts phocyte surface molecule can function both as a recep-
Figure 7. Molecular Modeling of an Amino
Acid Substrate for VAP-1
Proposed space-filling model of a GGGKGGG
peptide binding to VAP-1. The Ca-atoms of
the lysine residue are colored yellow. The sur-
face charge distribution is shown as positive
(blue), negative (red), or neutral (white). (A) A
surface view of the binding cavity area. The
peptide fits well into the surface groove lining
the entry to the binding cavity. (B) In the side
view, a cross-section across the cavity lead-
ing to the active site is depicted. The e-amino
group of the lysine is in the vincinity of the
active TOPA-quinone modified (TPQ) Tyr-471
of the VAP-1 and can react with it.
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tor and a substrate for VAP-1 or whether two different benzylamine should increase the lymphocyte binding.
Since a decrease in rolling was actually observed inlymphocyte molecules interact in succession with VAP-1
remains to be determined. Formation of an enzyme- this experiment, it means that benzylamine acts as a
competitor for the real substrate of VAP-1. Taken to-substrate bond would reduce the rolling velocity of the
lymphocyte and hence give sufficient time for the subse- gether, the physiological substrates of SSAO may well
be surface-bound amines in addition to or instead ofquent chemokine-mediated activation and integrin-
dependent firm adhesion and transmigration. soluble amines.
The reactive aldehyde groups formed on the lympho-The SSAO enzymes are categorized kinetically as
“ping-pong” (Hartmann et al., 1993; Klinman and Mu, cyte substrate after completion of the oxidative deami-
nation may further contribute to cell binding as cross-1994; Wilmot et al., 1999). In the reductive half-reaction,
the NH2-group of the substrate binds to the quinone- linking agents. Prolonged production of these reactive
compounds, either on cell surfaces or in a soluble form,cofactor of the oxidized (resting state) enzyme (2,4,5-
trihydroxyphenylalanine quinone, generated from an in- also likely accounts for the atherogenic events associ-
ated with SSAO function in certain pathological condi-trinsic tyrosine (Tyr471 in VAP-1) in the amino acid se-
quence by a self-processing event). This leads to the tions (Yu and Deng, 1998). Although soluble hydrogen
peroxide did not affect lymphocyte rolling in our assays,formation of a covalent Schiff base between the enzyme
and the substrate. Thereafter, release of the correspond- this SSAO reaction product may still contribute to the
evolving inflammatory phenotype of endothelium at latering aldehyde and reduced enzyme terminates the first
half of the reaction. In the oxidative half-reaction, the stages. For example, hydrogen peroxide regulates ex-
pression of multiple adhesion molecules, including P-selec-enzyme is reoxidized by the interaction with molecular
oxygen in a process that results in the release of ammo- tin and chemokines (Finkel, 1998; Kunsch and Medford,
1999; Bogdan et al., 2000; Saccani et al., 2000), whichnium and hydrogen peroxide. We measured a total reac-
tion time of about 0.3 s for benzylamine oxidation by may result in the enhanced recruitment of lymphocytes
at sites of inflammation. In addition, direct incubationVAP-1. In fact, the directly measured half-life for the
rate-limiting Schiff base transition step in a soluble of endothelial cells with high concentrations of hydrogen
peroxide increases leukocyte adhesiveness, and exoge-SSAO (bovine serum amino oxidase) is 0.693 s (J. Klin-
man, personal communication). Assuming that the reac- nously administered systemic H2O2 increases the num-
ber of rolling cells in intravital videomicroscopy studiestion time between VAP-1 and its lymphocyte substrate
in vivo is longer than that we measured for a soluble (Patel et al., 1991; Johnston et al., 1996). Thus, VAP-
1-mediated SSAO reaction offers a natural and localtest substrate (benzylamine) and assuming that the
Schiff base formation is the rate-limiting step also in endothelial source for this potent oxygen radical.
Anti-VAP-1 mAbs have earlier been shown to inhibitVAP-1 reaction, the kinetics (order of second rather than
millisecond) would favor a role for VAP-1 in the formation lymphocyte adhesion to human venules in frozen sec-
tions and to interfere with lymphocyte-endothelial cellof the adhesive contacts during rolling. However, we
cannot formally exclude that the SSAO reaction could interactions in inflamed rabbit mesenterial venules, and
VAP-1 transfectants have been reported to support lym-also modulate the dissociation of the lymphocyte-endo-
thelial contact. phocyte adhesion (Salmi and Jalkanen, 1992; Salmi et
al., 1997; Smith et al., 1998). Due to their inherent limita-We propose that an amino sugar or a free NH2 group
in an amino acid (either in the amino terminus or lysine tions (Salmi and Jalkanen, 1997), none of these assays
has been useful in dissecting the position of VAP-1 inor arginine side chain) on a lymphocyte surface molecule
can serve as a substrate for VAP-1, although the enzy- the extravasation cascade or the possible contribution
of the SSAO activity for adhesion. In particular, in thematically active site of VAP-1 resides buried within the
globular head of VAP-1 (Salminen et al., 1998). It has intravital experiments and flow chamber studies using
a transfectant cell line (Ax), human lymphocytes inter-been reported that NH2 in lysine side chain in proteins
can be utilized as a substrate for lysyl oxidase, a dis- acted with the endothelial cells but displayed neither
any clear rolling behavior nor firm adhesion (Salmi ettantly related, soluble 32 kDa SSAO enzyme involved in
collagen and elastin cross-linking and chemotaxis of al., 1997, 2000). In addition, for unknown reasons VAP-1
in the endothelial transfectants (Ax cells) shows verysmooth muscle cells (Kagan et al., 1984; Li et al., 2000).
In molecular modeling, we showed that there is a groove low levels of SSAO activity (Smith et al., 1998), which
severely limits the usefulness of those cells for enzymeon the surface of VAP-1, to which polypeptides fit so
that the NH2 group of a lysine side chain can directly analyses. Hence, the current results are the very striking
observation that natural VAP-1 molecule in primary en-interact with the catalytic site. We also show here that
a synthetic peptide can enter the catalytic center of dothelial cells mediates lymphocyte rolling under physi-
ologically relevant laminar shear stress in an SSAO-VAP-1. Moreover, we demonstrate that incubation of
lymphocytes with the endothelial cells results in the dependent manner.
The adhesive function of VAP-1 is regulated in at leastSSAO-mediated formation of hydrogen peroxide. This
reaction is substantially accelerated in the presence of three different ways. First, in endothelial cells most
VAP-1 is stored in intracellular granules under normalanti-VAP-1 mAbs, which induce a conformational change
in VAP-1. The first triggering event mimicked by the anti- conditions. Only upon elicition of inflammation is this
endothelial molecule translocated onto the lumen withVAP-1 mAb is otherwise almost completely missing from
the enzymatic assays with intact cells, since VAP-1 sup- a maximal surface expression at 8 hr (Jaakkola et al.,
2000). Second, presence of VAP-1 alone is not sufficientport lymphocyte binding in static assays only very
weakly (Salmi et al., 2000). Moreover, if a soluble amine for lymphocyte binding given that VAP-1-transfected
CHO cells lacking other relevant adhesion and triggeringwas the VAP-1 substrate in the flow assays, addition of
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control plasmids have been described (Smith et al., 1998). HUVECmolecules do not support lymphocyte binding (Salmi et
from umbilical veins were isolated using the method of Jaffe et al.al., 2000). Hence, VAP-1 is only involved in the adhesion
(1973). For the flow chamber assays, HUVEC were stimulated for 4cascade at sites where induction/activation of selectins,
hr with 100 U/ml TNF-a and for the last 10 min 5 mM histamine
chemokines, immunoglobulin superfamily molecules, was added. When the effects of SSAO inhibitors and substrates
and integrins takes place. In the appropriate context, on expression of adhesion molecules were analyzed, HUVEC were
activated with TNF-a (100 U/ml) 1 IL-1-b (100 U/ml) for 4 hr (fornevertheless, inactivation of VAP-1 function has an inde-
E-selectin) or for 20 hr (the other molecules). PBL from healthypendent and significant effect on the overall extravasa-
volunteers were isolated using Ficoll centrifugations.tion process. Third, the synthesis of lymphocyte count-
To obtain cell lysate for enzymatic assays, endothelial cells or PBLerreceptor/substrate for VAP-1 is restricted to certain
were sonicated on ice for 30 s at medium power (Braun sonicator
subpopulations. In frozen section adhesion assays, only Labsonic U)
CD8-positive T-killer cells and natural killer cells, but
not T helper lymphocytes, B cells, or monocytes, bound Radiochemical Measurements of Monoamine Oxidase Activity
to venules in a VAP-1-dependent manner (Salmi et al., Amine oxidase activity was assayed radiochemically using [7-14C]-
benzylamine hydrochloride (spec. act. 57 mCi/mmol, Amersham) as1997). Thus, regulated expression of VAP-1 likely con-
a substrate as described (Jaakkola et al., 1999). In brief, to mimictributes to the emigration of certain leukocyte subpopu-
the flow assays endothelial cells were seeded onto gelatin-coatedlations also in vivo.
24-well tissue culture plates and allowed to reach confluence. Prior
In conclusion, our findings show that endothelial to experiments, the cells were rinsed twice with RPMI 1640 and
VAP-1 has two functions, a direct adhesive function and preincubated for 30 min at 378C in 0.3 ml RPMI-1640 medium con-
an SSAO activity. Both functions are involved in the taining 1 mmol/L clorgyline and different agents (mAbs, PBL, inhibi-
tors) as specified in the text. The reaction was initiated by additionadhesion cascade during conversion of rolling cells to
of 6 mmol/L [14C]-benzylamine (40,000 dpm) and various unlabeledfirmly adherent. VAP-1-mediated binding may be partic-
amines (in the case of competitive studies) and terminated after 1 hrularly relevant for certain lymphocyte subpopulations
by citric acid. The aldehydes were extracted into toluene containing
(cytotoxic T cells and NK cells) to complement the classi- diphenyloxazole and the formation of [14C]-labeled benzaldehyde
cal adhesion cascade. The adhesive function described was quantified by scintillation counting.
here is also the first physiological function for SSAO,
which has been sought for decades now. Most impor- Fluorometric Detection of SSAO-Mediated H2O2 Formation
SSAO activity of the endothelial cells was also independently mea-tantly, VAP-1 represents the first example of how ec-
sured using Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxa-toenzymatic function of an adhesion molecule is ex-
zine; Molecular Probes Europe BV), a highly sensitive and stableploited in the regulation of the extravasation cascade.
probe for H2O2 (Zhou et al., 1997). Cultured endothelial cells wereThe adhesive function of VAP-1 can be independently rinsed with Krebs Ringer phosphate glucose ([KRPG]; 145 mM NaCl,
blocked by function blocking mAbs and chemical SSAO 5.7 mM sodium phosphate, 4.86 mM KCl, 0.54 mM CaCl2, 1.22 mM
inhibitors. The latter group of small nonproteinaceous MgSO4, and 5.5 mM glucose [pH 7.35]) and preincubated 30 min at
378C in 200 ml KRPG containing 1 mmol/L clorgyline and differentmolecules provides a novel and rational basis for search
agents as specified in the text. Catalytic reaction was initiated byof small molecular drugs for antiinflammatory therapy.
addition of various amines or PBL (1 3 106 cells/well) as substrates
and H2O2-detecting mixture containing horseradish peroxidase (finalExperimental Procedures
concentration 0.8 U/ml) and Amplex Red reagent (60 mM). The plates
were incubated for 1–2 hr at 378C in the final volume of 250 ml, andMonoclonal Antibodies, Immunostainings, and Immunoblottings
the bathing medium was clarified by centrifugation and placed inmAbs TK8-14 and 2D10 against different epitopes of VAP-1 and
aliquots (200 ml) into white nonphosphorescent microplates (Clini-nonbinding control mAbs NS-1 and Hermes-3 have been described
plate). Fluorescence intensity of the samples was measured (excita-(Kurkija¨rvi et al., 1998; Salmi et al., 2000). Another nonbinding control
tion, 545 nm; emission, 590 nm; Tecan ULTRA fluoropolarometer)mAb HB9771 against CD47 and binding control mAb CRL1938
and H2O2 concentration was calculated from calibration curves gen-against rabbit lipoprotein receptor protein were from ATCC. Immu-
erated by serial dilutions of either standard H2O2 or resorufin, thenoperoxidase staining of frozen sections and FACS analyses of
product of the Amplex Red reaction (Molecular Probes).gently trypsinized cells were performed as described (Salmi and
To evaluate the amount of H2O2 formed via SSAO-mediated reac-Jalkanen, 1992; Smith et al., 1998). In certain experiments, cultured
tion, specific enzyme inhibitors, semicarbazide (100 mM) and hy-cells were metabolically loaded for 4 hr with 10 mg/ml of DiI-conju-
droxylamine (5 mM), were included in the control wells subjected togated acetylated LDL (Biomedical Technologies Inc., Stoughton,
the same treatments and measurements and these values wereMA), a label specific for endothelial cells (and macrophages) (Voyta
subtracted from the total amount of H2O2 formed.et al., 1984), before analyses with a fluorescence microscope. For
In assays with synthetic peptides, 1 mM modeled peptideimmunoblotting 1% NP-40 lysates of rabbit endothelial cells, tonsil
(GGGGKGGGG) or control peptide (PHEPTYPDF) (both from Sigmastroma (containing blood vessels) and VAP-1 transfectants were
Genosys, .95% purity, no modifications) were incubated with endo-made, resolved in nonreducing SDS-PAGE, transferred to nitrocellu-
thelial cells with or without 1 mM benzylamine and the amount oflose, and analyzed using enhanced chemiluminescence according
H2O2 formed was measured fluorometrically.to previously published protocols (Salmi and Jalkanen, 1996).
Isolation of Cells Analyses of Receptor Number
For determining the number of VAP-1 molecules per cell, ScatchardImmunoaffinity isolation of endothelial cells from collagenase di-
gested rabbit heart was performed according to Girard and Springer analyses were done. Anti-VAP-1 mAb TK8-14 was affinity purified
with Protein G Sepharose and glycine elution, and a portion was(1995). In brief, hearts from male White New Zealand rabbits were
minced with scissors and subjected to two rounds of digestion with conjugated to FITC. After Sephadex gel filtration, the labeled mAb
was dialyzed against PBS. Concentration of the immunoglobulinscollagenase type I at 1378C for total of 75 min. The released cells
were filtered, reacted with anti-VAP-1 mAb or anti-CD31 mAb, and and fluorochrome/protein ratio were counted from spectrophoto-
metrically measured absorbances at 492 nm and 280 nm. Fixedpositively selected using MACS isolation columns according to the
manufacturer’s instructions. The cells were plated on gelatin-coated amount of labeled mAb (6 ng/ml) was combined with various con-
centrations of unlabeled mAb (range 0–100 mg/ml) and incubatedflasks in an endothelial growth medium (RPMI1640 supplemented
with 10% AB-serum, 15 mg/ml heparin, and 20 mg/ml endothelial with known number of rabbit endothelial cells (200,000) for 1 hr at
148C in the final volume of 100 ml. The cells were washed twice. Thecell growth factor). Ax and CHO cells transfected with VAP-1 and
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